ID   SU-DIPG-XIII
AC   CVCL_IT41
SY   SU DIPG XIII; SU-DIPGXIII; SU-DIPG-13; DIPG XIII; DIPGXIII; SJHGG054833
DR   cancercelllines; CVCL_IT41
DR   GEO; GSM4969590
DR   GEO; GSM4969591
DR   GEO; GSM4969592
DR   GEO; GSM4969593
DR   GEO; GSM4969619
DR   GEO; GSM4969628
DR   GEO; GSM4969629
DR   GEO; GSM4969630
DR   GEO; GSM4969657
DR   GEO; GSM5356026
DR   Wikidata; Q54970736
RX   PubMed=25939062;
RX   PubMed=26115193;
RX   PubMed=28823557;
RX   PubMed=31439867;
RX   PubMed=33319914;
RX   PubMed=34078608;
RX   PubMed=34215733;
RX   PubMed=34732238;
CC   Doubling time: 6.6 days (PubMed=34215733).
CC   Sequence variation: Mutation; HGNC; HGNC:4764; H3-3A; Simple; p.Lys28Met (c.83A>T) (H3.3K27M); ClinVar=VCV000376435; Zygosity=Unspecified (PubMed=25939062; PubMed=34732238).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Lys132Arg (c.395A>G); ClinVar=VCV000376625; Zygosity=Unspecified (PubMed=34732238).
CC   Omics: Genomics; ChIP-seq; H3K27ac.
CC   Omics: Genomics; ChIP-seq; H3K27me3.
CC   Omics: Genomics; Chromosome conformation analysis; Hi-C.
CC   Omics: Transcriptomics; RNAseq.
CC   Derived from site: In situ; Brainstem, pons; UBERON=UBERON_0000988.
ST   Source(s): PubMed=25939062; PubMed=28823557; PubMed=34732238
ST   Amelogenin: X
ST   CSF1PO: 9,10
ST   D13S317: 11 (PubMed=34732238)
ST   D13S317: 11,12 (PubMed=25939062; PubMed=28823557)
ST   D16S539: 11,12
ST   D21S11: 30 (PubMed=25939062; PubMed=28823557)
ST   D21S11: 30,31 (PubMed=34732238)
ST   D5S818: 12
ST   D7S820: 9
ST   TH01: 6 (PubMed=34732238)
ST   TH01: 6,7 (PubMed=25939062; PubMed=28823557)
ST   TPOX: 8 (PubMed=25939062; PubMed=28823557)
ST   TPOX: 8,9 (PubMed=34732238)
ST   vWA: 13,18 (PubMed=25939062; PubMed=28823557)
ST   vWA: 18,19 (PubMed=34732238)
DI   NCIt; C94764; Diffuse intrinsic pontine glioma
DI   ORDO; Orphanet_497188; Diffuse intrinsic pontine glioma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   6Y
CA   Cancer cell line
DT   Created: 03-03-17; Last updated: 10-04-25; Version: 14
//
RX   PubMed=25939062; DOI=10.1038/nm.3855; PMCID=PMC4862411;
RA   Grasso C.S., Tang Y.-J., Truffaux N., Berlow N.E., Liu L.-N.,
RA   Debily M.-A., Quist M.J., Davis L.E., Huang E.C., Woo P.J.,
RA   Ponnuswami A., Chen S., Johung T.B., Sun W.-C., Kogiso M., Du Y.-C.,
RA   Qi L., Huang Y.-L., Hutt-Cabezas M., Warren K.E., Le Dret L.,
RA   Meltzer P.S., Mao H., Quezado M., van Vuurden D.G., Abraham J.,
RA   Fouladi M., Svalina M.N., Wang N., Hawkins C., Nazarian J.,
RA   Alonso M.M., Raabe E.H., Hulleman E., Spellman P.T., Li X.-N.,
RA   Keller C., Pal R., Grill J., Monje M.;
RT   "Functionally defined therapeutic targets in diffuse intrinsic pontine
RT   glioma.";
RL   Nat. Med. 21:555-559(2015).
//
RX   PubMed=26115193; DOI=10.1097/NEN.0000000000000216; PMCID=PMC4596247;
RA   Taylor I.C., Hutt-Cabezas M., Brandt W.D., Kambhampati M.,
RA   Nazarian J., Chang H.T., Warren K.E., Eberhart C.G., Raabe E.H.;
RT   "Disrupting NOTCH slows diffuse intrinsic pontine glioma growth,
RT   enhances radiation sensitivity, and shows combinatorial efficacy with
RT   bromodomain inhibition.";
RL   J. Neuropathol. Exp. Neurol. 74:778-790(2015).
//
RX   PubMed=28823557; DOI=10.1016/j.cell.2017.07.016; PMCID=PMC5587159;
RA   Qin E.Y., Cooper D.D., Abbott K.L., Lennon J., Nagaraja S., Mackay A.,
RA   Jones C., Vogel H., Jackson P.K., Monje M.;
RT   "Neural precursor-derived pleiotrophin mediates subventricular zone
RT   invasion by glioma.";
RL   Cell 170:845-859.e19(2017).
//
RX   PubMed=31439867; DOI=10.1038/s41467-019-11732-6; PMCID=PMC6706443;
RA   Fons N.R., Sundaram R.K., Breuer G.A., Peng S., McLean R.L.,
RA   Kalathil A.N., Schmidt M.S., Carvalho D.M., Mackay A., Jones C.,
RA   Carcaboso A.M., Nazarian J., Berens M.E., Brenner C., Bindra R.S.;
RT   "PPM1D mutations silence NAPRT gene expression and confer NAMPT
RT   inhibitor sensitivity in glioma.";
RL   Nat. Commun. 10:3790.1-3790.10(2019).
//
RX   PubMed=33319914; DOI=10.1093/gigascience/giaa136; PMCID=PMC7736793;
RA   Sanders L.M., Cheney A., Seninge L., van den Bout A., Chen M.,
RA   Beale H.C., Kephart E.T., Pfeil J., Learned K., Lyle A.G., Bjork I.,
RA   Haussler D., Salama S.R., Vaske O.M.;
RT   "Identification of a differentiation stall in epithelial mesenchymal
RT   transition in histone H3-mutant diffuse midline glioma.";
RL   GigaScience 9:giaa136.1-giaa136.14(2020).
//
RX   PubMed=34078608; DOI=10.1126/sciadv.abg4126; PMCID=PMC10166578;
RA   Wang J., Huang T.Y.-T., Hou Y., Bartom E.T., Lu X.-Y., Shilatifard A.,
RA   Yue F., Saratsis A.M.;
RT   "Epigenomic landscape and 3D genome structure in pediatric high-grade
RT   glioma.";
RL   Sci. Adv. 7:eabg4126.1-eabg4126.16(2021).
//
RX   PubMed=34215733; DOI=10.1038/s41467-021-24168-8; PMCID=PMC8253809;
RA   He C., Xu K., Zhu X.-Y., Dunphy P.S., Gudenas B., Lin W.-W., Twarog N.,
RA   Hover L.D., Kwon C.-H., Kasper L.H., Zhang J.-Y., Li X.-Y., Dalton J.,
RA   Jonchere B., Mercer K.S., Currier D.G., Caufield W., Wang Y.-Z., Xie J.,
RA   Broniscer A., Wetmore C., Upadhyaya S.A., Qaddoumi I., Klimo P.,
RA   Boop F.A., Gajjar A., Zhang J.-H., Orr B.A., Robinson G.W., Monje M.,
RA   Freeman B.B. 3rd, Roussel M.F., Northcott P.A., Chen T.-S., Rankovic Z.,
RA   Wu G., Chiang J.C.-H., Tinkle C.L., Shelat A.A., Baker S.J.;
RT   "Patient-derived models recapitulate heterogeneity of molecular
RT   signatures and drug response in pediatric high-grade glioma.";
RL   Nat. Commun. 12:4089.1-4089.17(2021).
//
RX   PubMed=34732238; DOI=10.1186/s40478-021-01270-y; PMCID=PMC8565061;
RA   Xu C., Liu H., Pirozzi C.J., Chen L.H., Greer P.K., Diplas B.H.,
RA   Zhang L.-W., Waitkus M.S., He Y.-P., Yan H.;
RT   "TP53 wild-type/PPM1D mutant diffuse intrinsic pontine gliomas are
RT   sensitive to a MDM2 antagonist.";
RL   Acta Neuropathol. Commun. 9:178.1-178.12(2021).
//